EP 2 981 255 B1 relates to empagliflozin for use in a method for preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in a patient with type 2 or type 1 diabetes mellitus or with pre-diabetes.
Brief outline of the case
Claim 1 as granted infringed Art 123(2).The patent was maintained according to AR1.